HFA Premium Access

Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

Congress Session

About the speaker

Professor Anna Norhammar

Karolinska Institutet, Stockholm (Sweden)
4 presentations
0 follower

8 more presentations in this session

Systolic heart failure treatment with the if inhibitor ivabradine trial

Speaker: Professor M. Boehm (Homburg, DE)

Thumbnail

Real-world heart failure treatment in 10.330 patients with chronic heart failure in the netherlands

Speaker: Doctor J. Brugts (Rotterdam, NL)

Thumbnail

Clinical profiles, management and outcome of acute heart failure in Korea: results from the Korean acute heart failure registry (KorAHF)

Speaker: Associate Professor H. Lee (Seoul, KR)

Thumbnail

Non-invasive lung impedance-guided preemptive treatment in chronic heart failure patients: a randomized controlled trial (IMPEDANCE-HF Trial)

Speaker: Professor M. Kleiner Shochat (Hadera, IL)

Thumbnail

Single dose, purified biocompatible vegf a mrna administered one week post myocardial infarction in pigs inhibits cardiac fibrosis and leads to chronic reversal of global ventricular dysfunction

Speaker: Professor K. Chien (Stockholm, SE)

Thumbnail

Access the full session

Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30

Speakers: Professor A. Norhammar, Professor M. Boehm, Doctor J. Brugts, Associate Professor H. Lee, Professor M. Kleiner Shochat...
Thumbnail

About the event

Image

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk